Kanjinti and Mvasi Make ‘Solid Start’ In US

Amgen’s Global Biosimilars Annualizing At Around $700m

Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.

Sprinting
Amgen says its Kanjinti and Mvasi biosimilars have made a solid start in the US • Source: Shutterstock

A “solid start” by its Kanjinti (trastuzumab-anns) and Mvasi (bevacizumab-awwb) biosimilars in the US following their at-risk launch in July this year contributed sales of $81m for Amgen in the third quarter of this year. With Kanjinti and Amgevita (adalimumab) in the rest of the world adding another $92m, Amgen reported global biosimilars turnover in the quarter of $173m versus just $19m in the prior-year period.

In July, Amgen chose to introduce Kanjinti and Mvasi at-risk amid ongoing US patent litigation versus Roche and its Genentech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By 

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By 

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches First Brazilian Approval For Lucentis Biosimilar

 

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By 

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

More from Products

Formycon Snatches First Brazilian Approval For Lucentis Biosimilar

 

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By 

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Lupin Concedes To Wakix IP With 2030 Launch Date Agreement

 
• By 

Ahead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.